Loading…
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company has a strategic collaboration with Mayo Clinic for the development of SC451, a hypoimmune-modified pancreatic islet cell therapy for type 1 diabetes. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-193M | $-244M | $-145M | -151.8% | - | -8.5% |
| 2024 | $0M | $-255M | $-267M | $-257M | -106.5% | - | -5.8% |
| 2023 | $0M | $-269M | $-283M | $-274M | -98.5% | - | 5.1% |
| 2022 | $0M | $-257M | $-269M | $-311M | -54.0% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 272.56 | 286.13 | 270.83 | 205.71 |
| Research And Development | - | 201 | 212.83 | 206.79 | 161.41 |
| Selling General And Administration | - | 71.56 | 73.30 | 64.04 | 44.30 |
| Total Expenses | - | 272.56 | 286.13 | 270.83 | 205.71 |
| Operating Income | - | -272.56 | -286.13 | -270.83 | -205.71 |
| Total Operating Income As Reported | - | -272.56 | -293.14 | -272.72 | -250.32 |
| EBITDA | - | -256.94 | -268.58 | -255.33 | -192.96 |
| Normalized EBITDA | - | -256.94 | -261.57 | -253.44 | -148.35 |
| EBIT | - | -272.56 | -286.13 | -270.83 | -205.71 |
| Interest Income | - | 3.76 | 9.94 | 10.47 | 3.85 |
| Net Interest Income | - | 3.76 | 9.94 | 10.47 | 3.85 |
| Other Non Operating Income Expenses | - | -0.67 | -0.05 | -4.51 | 2.31 |
| Other Income Expense | - | -0.67 | -7.07 | -6.40 | -42.31 |
| Interest Income Non Operating | - | 3.76 | 9.94 | 10.47 | 3.85 |
| Net Non Operating Interest Income Expense | - | 3.76 | 9.94 | 10.47 | 3.85 |
| Pretax Income | - | -269.48 | -283.26 | -266.76 | -244.17 |
| Tax Provision | 0 | - | - | - | - |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -269.48 | -283.26 | -266.76 | -244.17 |
| Net Income From Continuing And Discontinued Operation | - | -269.48 | -283.26 | -266.76 | -244.17 |
| Net Income From Continuing Operation Net Minority Interest | - | -269.48 | -283.26 | -266.76 | -244.17 |
| Net Income | - | -269.48 | -283.26 | -266.76 | -244.17 |
| Net Income Common Stockholders | - | -269.48 | -283.26 | -266.76 | -244.17 |
| Net Income Including Noncontrolling Interests | - | -269.48 | -283.26 | -266.76 | -244.17 |
| Normalized Income | - | -269.48 | -276.24 | -264.87 | -199.56 |
| Diluted NI Availto Com Stockholders | - | -269.48 | -283.26 | -266.76 | -244.17 |
| Basic Average Shares | 166.43 | 188.34 | 194.54 | 230.89 | - |
| Diluted Average Shares | 166.43 | 188.34 | 194.54 | 230.89 | - |
| Reconciled Depreciation | - | 15.62 | 17.54 | 15.50 | 12.75 |
| Total Unusual Items | - | - | -7.01 | -1.89 | -44.61 |
| Total Unusual Items Excluding Goodwill | - | - | -7.01 | -1.89 | -44.61 |
| Special Income Charges | - | - | -7.01 | -1.89 | -44.61 |
| Impairment Of Capital Assets | - | - | 7.01 | 1.89 | 44.61 |
| General And Administrative Expense | - | 71.56 | 73.30 | 64.04 | 44.30 |
| Other Gand A | - | 71.56 | 73.30 | 64.04 | 44.30 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Sana Biotechnology, Inc.this co. | SANA | $824M | -3.37 | 5.12 | -151.8% | -4.31 |
| Theravance Biopharma, Inc. | TBPH | $844M | 7.97 | 2.84 | 35.7% | 5.34 |
| Janux Therapeutics, Inc. | JANX | $839M | -7.39 | 0.88 | -11.9% | -5.20 |
| ORIC Pharmaceuticals, Inc. | ORIC | $830M | -6.41 | 2.16 | -33.7% | -5.56 |
| LB Pharmaceuticals Inc | LBRX | $829M |
| - |
| - |
| - |
| - |
| -32.88 |
| 2.75 |
| -8.4% |
| -19.35 |
| Amphastar Pharmaceuticals, Inc. | AMPH | $825M | 8.41 | 1.05 | 12.4% | 6.17 |
| Replimune Group, Inc. | REPL | $815M | -3.30 | 1.96 | -59.5% | -3.31 |
| Esperion Therapeutics, Inc. | ESPR | $806M | - | - | 7.5% | 13.94 |
| Lumexa Imaging Holdings, Inc. | LMRI | $792M | -16.81 | 1.35 | -8.0% | 11.96 |
| Peer Median | - | -6.41 | 1.96 | -8.2% | 1.02 | |